Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783622 · ClinicalTrials.gov registry record · Phase 1
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, sponsored by Janux Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 18
- Study locations
NCT05783622 is a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma that is actively recruiting participants, run by Janux Therapeutics. The registered enrollment target is 130 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 18 study locations across 12 states.
The verdict
NCT05783622, a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, is actively recruiting participants, sponsored by Janux Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Conditions Studied
Interventions
- DRUG JANX008
Study Locations (18)
California
- City of Hope Medical Center - Duarte
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California San Diego Moores Cancer Center - San Diego
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health System - Detroit
Ohio
- The Christ Hospital Cancer Center - Cincinnati
- Ohio State University Hospital - Columbus
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas, MD Anderson Cancer Center - Houston
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05783622
The ClinicalTrials.gov registry entry for NCT05783622 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Janux Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which JANX008 is the first listed.
NCT05783622 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT05783622 about?
NCT05783622 is a clinical study titled "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies". This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma ...
What is the current status of trial NCT05783622?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-04-19. Estimated completion is 2027-10.
What conditions does trial NCT05783622 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Small-cell Lung Cancer.
What interventions are being tested in trial NCT05783622?
The interventions under investigation include: JANX008 (DRUG).
Who is sponsoring clinical trial NCT05783622?
This trial is sponsored by Janux Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783622 being conducted?
This trial has 18 study locations across California, Georgia, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.